Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| KYMR | PRESS-RELEASE | bullish | 6/10 | Kymera Therapeutics presented new preclinical data for KT-579, its oral IRF5 degrader, at EULAR and FOCIS meetings, show | Jun 8, 2026 |
| BAK | 6-K | neutral | 2/10 | Braskem S.A. filed a consolidated summary voting report for its Extraordinary General Meeting originally called for May | Jun 8, 2026 |
| CGEM | 8-K | bullish | 6/10 | Cullinan Therapeutics presented initial Phase 1 data for CLN-978 (CD19xCD3 T cell engager) in SLE and RA at EULAR 2026. | Jun 8, 2026 |
| ARTV | PRESS-RELEASE | bullish | 7/10 | Artiva Biotherapeutics presented positive clinical data for AlloNK (AB-101) at EULAR 2026, including a 71% ACR50 respons | Jun 8, 2026 |
| EXOZ | 424B5 | bearish | 6/10 | EXOZYMES INC. is raising approximately $4.7 million (before expenses) through a registered direct offering of 592,270 sh | Jun 8, 2026 |
| NRIX | 8-K | bullish | 8/10 | Nurix Therapeutics entered into a global license and collaboration agreement with Roche to co-develop and co-commerciali | Jun 8, 2026 |
| SNYNF | 6-K | bullish | 7/10 | Sanofi announced FDA priority review for venglustat NDA to treat type 3 Gaucher disease, with a target action date of No | Jun 8, 2026 |
| BAK | 6-K | bullish | 6/10 | Braskem filed a First Amendment to its Shareholders' Agreement with Petrobras and Shine Fund (IG4 Sol.), which shifts ap | Jun 8, 2026 |
| CTOR | EFFECT | bearish | 7/10 | Citius Oncology's S-3 registration (File No. 333-296360) became effective on June 5, 2026, enabling the resale of up to | Jun 8, 2026 |
| PSTV | EFFECT | bearish | 5/10 | The SEC declared Plus Therapeutics' Form S-3 shelf registration (File No. 333-296411) effective on June 5, 2026. This sh | Jun 8, 2026 |
| ESPR | DEFM14A | bullish | 7/10 | The filing is a definitive merger proxy (DEFM14A) for Esperion Therapeutics' acquisition by ArchiMed for $3.16/share plu | Jun 8, 2026 |
| BAK | 6-K | neutral | 3/10 | Braskem received notice that its controlling shareholders, Petrobras and Shine I FIP, executed the 1st Amendment to the | Jun 8, 2026 |
| FBRX | S-3/A | bearish | 6/10 | Forte Biosciences filed Amendment No. 1 to its S-3 shelf registration statement, registering up to $500M in securities ( | Jun 8, 2026 |
| LYEL | PRESS-RELEASE | bullish | 7/10 | Lyell Immunopharma announced updated safety data from its Phase 1 trial of LYL273 in metastatic colorectal cancer, showi | Jun 8, 2026 |
| ALVO | PRESS-RELEASE | neutral | 4/10 | Alvotech announced FDA acceptance of its BLA for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab), | Jun 8, 2026 |
| ALVO | PRESS-RELEASE | neutral | 4/10 | Alvotech announced FDA acceptance of its BLA for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab) f | Jun 8, 2026 |
| NRIX | PRESS-RELEASE | bullish | 8/10 | Nurix Therapeutics announced a global collaboration with Roche to co-develop and co-commercialize bexobrutideg, an oral | Jun 8, 2026 |
| LENZ | PRESS-RELEASE | bullish | 6/10 | LENZ Therapeutics announced that Everest Medicines has acquired the rights to develop and commercialize VIZZ (LNZ100) in | Jun 7, 2026 |
| BMEA | PRESS-RELEASE | bullish | 6/10 | Biomea Fusion presented new clinical and translational data for icovamenib at ADA 2026, showing durable HbA1c improvemen | Jun 5, 2026 |
| KLRA | PRESS-RELEASE | bullish | 7/10 | Kailera Therapeutics and Hengrui Pharma presented positive Phase 2 oral and Phase 1 injection data for ribupatide (GLP-1 | Jun 5, 2026 |
| KRYS | CLUSTER | neutral | 2/10 | President and CEO Krishnan Krish S and President of R&D Krishnan Suma each sold 320 shares of Krystal Biotech on June 4, | Jun 5, 2026 |
| XERS | CLUSTER | neutral | 3/10 | Two Xeris insiders (Director Persky and officer Hecht) sold a combined $192K in open-market sales over a 3-day window. T | Jun 5, 2026 |
| XERS | CLUSTER | neutral | 3/10 | A cluster of insider selling at Xeris Biopharma, totaling $192K in open-market sales by two directors and an officer, oc | Jun 5, 2026 |
| ANAB | 144 | bearish | 5/10 | Dennis Mulroy, an officer of AnaptysBio, filed a Form 144 on June 5, 2026, indicating intent to sell 22,491 shares of co | Jun 5, 2026 |
| RXRX | CLUSTER | neutral | 2/10 | Three directors at Recursion Pharmaceuticals sold a total of $271K in open-market transactions over a 7-day window. The | Jun 5, 2026 |
| EOLS | S-3 | neutral | 3/10 | Evolus filed a new universal shelf registration statement (S-3) replacing its expiring 2023 shelf, registering up to $25 | Jun 5, 2026 |
| JAZZ | CLUSTER | bearish | 5/10 | A cluster of three Jazz Pharmaceuticals insiders sold $3.32M in stock over a one-week window, including the EVP & Chief | Jun 5, 2026 |
| EQ | CLUSTER | bearish | 5/10 | Three Equillium insiders, including the President/CSO, COO, and Principal Accounting Officer, sold a total of ~$975K in | Jun 5, 2026 |
| UTHR | CLUSTER | neutral | 2/10 | Three top insiders at United Therapeutics (CEO, CFO, General Counsel) sold a total of $391K in open-market shares over a | Jun 5, 2026 |
| NNVC | S-3 | bearish | 6/10 | NanoViricides filed a universal shelf registration statement on Form S-3 to register up to $50 million in securities (co | Jun 5, 2026 |